Relapsed Hodgkin Lymphoma: Management Strategies
- 775 Downloads
Although Hodgkin lymphoma (HL) is largely curable with first-line therapy, approximately one-third of patients will not have a complete response to frontline treatment or will subsequently relapse. Only 50 % of these patients will be effectively salvaged with conventional therapies. The prognosis is particularly poor for those patients with chemotherapy refractory disease, who are unable to obtain even transient disease control, and for patients who relapse following high dose chemotherapy and autologous stem cell transplant. In this review, we summarize the most recent updates on the management of patients with relapsed HL, the role of novel therapies such as brentuximab vedotin, and an overview of promising new agents currently under investigation. We also discuss the role of consolidation strategies such as high-dose chemotherapy and autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic stem cell transplant, and the need for new strategies in the elderly patient population.
KeywordsHodgkin lymphoma Relapsed disease Refractory disease Risk stratification Autologous stem cell transplant Reduced-intensity conditioning allogeneic stem cell transplant Brentuximab vedotin Bendamustine Histone deacetylase inhibitors Everolimus Panobinostat Lenalidomide Rituximab Immunochemotherapy Elderly patients
CD is supported by a Clinical Investigator Career Development Award from the Lymphoma Research Foundation.
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Francesca Montanari declares no potential conflicts of interest.
Dr. Catherine Diefenbach is a consultant for Seattle Genetics.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance
- 1.Available at: http://seer.cancer.gov/statfacts/html/hodg.html. Accessed May 11th, 2014.
- 7.Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRefGoogle Scholar
- 8.Diefenbach CS LH, Hong F. Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood. 2013;122(21):4277.Google Scholar
- 11.Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1646–52.PubMedCrossRefPubMedCentralGoogle Scholar
- 14.Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 15.Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145:369–72.PubMedCrossRefGoogle Scholar
- 16.••Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–70. The prospective study that provides evidence that the goal of salvage chemotherapy in patients with HL should be a negative FDG-PET scan before ASCT. PubMedCrossRefPubMedCentralGoogle Scholar
- 17.•Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430–4. Largest study so far conducted to assess the predictors of outcome of patients with Hodgkin lymphoma relapsing after autologous stem cell transplant. PubMedCrossRefGoogle Scholar
- 23.Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762–7.PubMedCrossRefGoogle Scholar
- 26.•Hawkes EA, Barton S, Cunningham D, et al. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Ann Hematol. 2014;93:827–34. Single institution study showing impressive ORR of 80% and 37% of CR with salvage outpatient chemotherapy regimen gemcitabine based, non cross toxic with first line chemotherapy drugs. PubMedCrossRefGoogle Scholar
- 32.•Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248–55. The phase I trial that showed favorable safety profile and significant activity of Brentuximab in patient with relapsed/refractory CD30 positive lymphomas. PubMedCrossRefGoogle Scholar
- 34.••Younes A, Gopal AK, Smith SE, Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183. The phase II trial that led to the accelerated FDA approval of Brentuximab in relapsed or refractory Hodgkin lymphoma. PubMedCrossRefPubMedCentralGoogle Scholar
- 37.Chen R FS, Palmer j et al Two-year follow up of patients with relapsed/refractory Hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantation. Presented at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013, 2013Google Scholar
- 38.•Garciaz S, Coso D, Peyrade F, et al: Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol, 2013 Brentuximab as a bridge to allogeneic transplant in patients with refractory disease. Google Scholar
- 39.Chen RW PJ, Siddiqi T, et al. : Brentuximab vedotin as first line salvage therapy in relapsed/refractory HL. ASH Annual Meeting Abstracts. 2012;120(21):3699, 2012Google Scholar
- 40.Moskowitz AJ SH, Gerecitano J, et al: PET-adapted sequential therapy with brentuximab vedotin and augmented-ICE induces FDG-PET normalization in 92% of patients with relapsed and refractory Hodgkin lymphoma, Presented at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19–22, 2013.Google Scholar
- 42.•Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560–8. First study assessing the safety and efficacy of brentuximab in the setting of relapse post allogeneic stem transplant. PubMedCrossRefPubMedCentralGoogle Scholar
- 44.Ruffert KJH, Syrbe G, et al. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin’s lymphoma. Z Klin Med. 1989;44:671–4.Google Scholar
- 45.Brockmann B. Therapy of the recurrence of malignant lymphoma. Z Aerztl Fortbild (Jena). 1992;86:843.Google Scholar
- 47.••Moskowitz AJ, Hamlin Jr PA, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456–60. First prospective phase II trial evaluating efficacy of bendamustine in heavily pretreated Hodgkin lymphoma patients. PubMedCrossRefPubMedCentralGoogle Scholar
- 48.•Ghesquieres H, Stamatoullas A, Casasnovas O, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54:2399–404. Recent retrospective study confirming acitvity of bendamustine in heavily pretreated patients with HL. PubMedCrossRefGoogle Scholar
- 49.•Corazzelli G, Angrilli F, D'Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–15. Recent retrospective study confirming acitvity of bendamustine in heavily pretreated patients with HL. PubMedCrossRefGoogle Scholar
- 52.•Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19:6882–90. Phase I study suggesting synergy of the combination of HDACI panobinostat with mTOR inhibitor everolimus, although limited by the development of significative thrombocytopenia in more than half of the patients.PubMedCrossRefGoogle Scholar
- 54.•Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197–203. The largest phase II trial conducted with the panobinostat, which demonstrated to be the most effective HDACI in Hodgkin lymphoma. PubMedCrossRefGoogle Scholar
- 57.Harrison SJ, Hsu AK, Neeson P, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55:1053–60.PubMedCrossRefGoogle Scholar
- 59.Sawas AC-GS, Neylon E. A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma. Blood. 2013;122:5134.Google Scholar
- 63.Hahn T, McCarthy Jr PL, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.PubMedCrossRefPubMedCentralGoogle Scholar
- 64.Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257–64.PubMedCrossRefGoogle Scholar
- 65.Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.PubMedCrossRefGoogle Scholar
- 66.••Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310–7. The largest prospective trial so far on the role of RIC allo-sct in Hodgkin lymphoma. PubMedCrossRefPubMedCentralGoogle Scholar
- 67.Sobol U, Rodriguez T, Smith S, et al: Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. Leuk Lymphoma, 2013.Google Scholar
- 68.Anderlini P SR, Ledesma C: Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM) Blood 2013 122:410, 2013.Google Scholar
- 73.•Boll B, Goergen H, Arndt N, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol. 2013;31:4431–7. Largest retrospective study on safety and efficacy of second line treatment modalities in older patients with relapsed or refractory Hodgkin Lymphoma. PubMedCrossRefGoogle Scholar
- 75.•Gopal AK, Bartlett NL, Forero-Torres A, et al: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma, 2014 Largest retrospective analysis evaluating the safety and efficacy of brentuximab in older patients (60 years and older) with relapsed or refractory Hodgkin lymphoma or Anaplastic Large Cell lymphoma. Google Scholar